Stellar Biotechnologies Announces a Strategic Agreement for Marketing and Sales With SAFC(R)

PORT HUENEME, CA, Aug 03 (MARKET WIRE) --
Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (PINKSHEETS: SBOTF)
is pleased to announce they have entered into an agreement for marketing
and sales with SAFC(R), a business unit of Sigma-Aldrich (NASDAQ: SIAL) a
global leader in biopharmaceutical contract manufacturing. Under the
agreement, Stellar will produce KLH commercial intermediate and SAFC will
sell, distribute and market cGMP-grade HMW KLH (high molecular weight
keyhole limpet hemocyanin) that uses only Stellar aquaculture-derived KLH
for applications in therapeutic vaccines.

This collaboration is expected to increase access to a scalable source
for KLH, a critical immunostimulatory vaccine carrier protein that will
enable the transition from clinical research to commercialization of
conjugate vaccine platforms, while managing costs and the risk of supply
constraints faced by suppliers that rely on the exploitation of the
critically limited natural resource.

Stellar will supply all aquaculture-derived KLH intermediate required for
production of SAFC cGMP KLH formulations. SAFC will manufacture HMW KLH
under cGMP conditions and provide cGMP clinical and commercial
manufacturing of bioconjugation services to support the development and
manufacture of conjugate vaccines.

SAFC Director of Business Development Tom Gelineau said, "Our agreement
with Stellar Biotechnologies reinforces SAFC's commitment to providing
high quality products and specialized contract manufacturing resources to
global biopharmaceutical customers -- from research through
commercialization."

Stellar CEO Frank Oakes commented, "The agreement solidifies our position
as the only source for a scalable supply of cGMP-grade HMW-KLH for the
vaccine business. We have put Stellar's aquaculture KLH supply front and
center in combination with what we believe is the most important
manufacturer and marketer of cGMP biologics in the world, Sigma-Aldrich's
SAFC business unit. This exciting development will allow us to move
aggressively forward on our diagnostic programs, knowing that the
state-of-the-art quality assurance and production capabilities of SAFC
will be providing the backbone for companies seeking the highest quality
HMW-KLH available for vaccine developers anywhere in the world. We look
forward to continuing growth in this relationship and will begin
manufacture of SAFC's initial order as soon as possible."

About High Molecular Weight KLH:
HMW KLH is an ideal carrier molecule
for vaccine antigens (substances that promote the generation of antibody
and cell-mediated immune responses) against cancers and infectious
agents. The combination of an antigen against specific tumor cell-types,
conjugated to the highly immunogenic HMW KLH molecule, is the basis for a
proven strategy for a new class of drugs known as therapeutic vaccines.
Potent yet safe in humans, KLH is highly prized as a critical component
of certain therapeutic vaccines including ones for lymphoma, bladder,
breast, colon and other cancers as well as other indications including
Alzheimer's, rheumatoid arthritis, lupus and others.

About SAFC(R): SAFC is the custom manufacturing and services business
unit of Sigma-Aldrich Corporation (NASDAQ: SIAL). They are recognized as
a top 10 global fine chemical supplier and trusted manufacturer of
specialty chemicals and biologics for the life science and high
technology industries. Utilizing global "Centers of Excellence" and
dedicated manufacturing facilities, SAFC is often able to resolve
development and manufacturing challenges and accelerate the production of
custom materials. Their rich portfolio includes high-purity inorganic
materials for high technology applications, cell culture products,
services for biopharmaceutical manufacturing and biochemical production,
and complex, multi-step organic synthesis of APIs and key intermediates.
For more information about SAFC, visit www.safcglobal.com.

About Sigma-Aldrich (NASDAQ: SIAL): Sigma-Aldrich is a leading Life
Science and High Technology company. Its biochemical and organic chemical
products and kits are used in scientific and genomic research,
biotechnology, pharmaceutical development, the diagnosis of disease and
as key components in pharmaceutical and other high technology
manufacturing. The Company has customers in life science companies,
university and government institutions, hospitals, and in industry. Over
one million scientists and technologists use its products. Sigma-Aldrich
operates in 40 countries and has 8,300 employees providing excellent
service worldwide. Sigma-Aldrich is committed to Accelerating Customer
Success through Innovation and Leadership in Life Science, High
Technology and Service. For more information about Sigma-Aldrich, please
visit its award-winning Web site at www.sigma-aldrich.com.

SAFC and Sigma-Aldrich are registered trademarks of Sigma-Aldrich Co. LLC.

About Stellar Biotechnologies, Inc. Stellar Biotechnologies, Inc. (TSX-V:
KLH) (PINKSHEETS: SBOTF) (www.StellarBiotechnologies.com) is the world
leader in sustainable manufacturing of pharmaceutical grade KLH (Keyhole
Limpet Hemocyanin). This evolutionary protein has a highly complex
structure that makes it ideal for use in human and animal vaccines and
diagnostic products. With partners and customers, its flagship Stellar
KLH products are in the clinic, and on the way to being established as
the only sustainable, long-term pharmaceutical source. Stellar
Biotechnologies was founded to address the growing demand for renewable,
commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has
developed leading practices, facilities and proprietary capabilities to
address this need.

There can be no assurance that forward-looking statements will prove to
be accurate, as actual results and future events could differ materially
from those anticipated in such statements. Readers should not place undue
reliance on such statements. Except in accordance with applicable
securities laws, the Company expressly disclaims any obligation to update
any forward-looking statements or forward-looking statements that are
incorporated by reference herein. This news release does not constitute
an offer to sell, or a solicitation of an offer to buy any of the
Company's securities set out herein in the United States, or to, or for
the benefit or account of, a U.S. Person or person in the United States.
Neither TSX Venture Exchange nor its Regulation Services Provider accepts
responsibility for the adequacy or accuracy of these releases.

Contact:

Michael McClurg
VP, Business Development & Marketing
322 Scott Street
Port Hueneme, CA 93041
(805) 488-2147
cell - 858 735 6117
mmcclurg@StellarBiotech.com

Copyright 2011, Market Wire, All rights reserved.

-0-